In a recent presentation, researchers from the Medical University of Lodz have aimed to investigate the therapeutic potential of simultaneously targeting axin and cannabinoid receptors (CBs) with KYA-1797K and WIN-55212-2 in colorectal cancer (CRC) cell lines SW480 and Caco-2.
Recent advances in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, have shown that inhibiting the interaction between the α4β7 integrin and the endothelial ligand mucosal addressin cell adhesion molecule 1 (MADCAM1) has proven useful, safe and effective.
At the United European Gastroenterology Week in Vienna, Redx Pharma plc presented data regarding their ROCK inhibitor RXC-008 for treating fibrostenotic Crohn’s disease. RXC-008 is restricted to the gastrointestinal tract, thus avoiding systemic exposure; ROCK1/2 kinases are involved in fibrosis and their blockade has been efficacious in several rodent models of fibrotic disease.
Researchers from Proqr Therapeutics NV recently presented preclinical data on AX-0810, a single-stranded RNA editing oligonucleotide (EON) targeting RNA coding for NTCP cotransporter
Insitro Inc. has signed three strategic agreements with Eli Lilly & Co. focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by Insitro using its artificial intelligence/machine learning-based platform.
Clostridioides difficile has been traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania have developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.
Shattuck Labs Inc. has announced a strategic shift to focus on SL-325, a death receptor 3 (DR3) antagonist antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases.
Palisade Bio Inc. has submitted a clinical trial application (CTA) for PALI-2108 for the treatment of ulcerative colitis, following a pre-CTA consultation meeting with Health Canada. Pending clearance, the company anticipates initiating a phase I study by year-end.
Mabylon AG has been awarded three grants totaling more than CHF1.3 million (US$1.5 million) from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
RSS
